Catalym
Oncology Therapeutics · Drug Discovery
Overview
Catalyzing immunotherapy. CatalYm has identified GDF-15 as a key cancer therapy resistance mechanism and is developing a safe and efficacious immune therapy for solid tumors.
Jobs
Remote (location not specified) · Full-Time · Bachelor's Degree
Apply
Growth
Hiring Momentum
23/100
Hiring freeze
Open positions
5
0 opened / 0 closed in 30 days
Median time-to-fill
65 days
faster than 19% of the market
ATS activity
Every ~5 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Finance
33% ▲
QA
17% ▼
Administrative
17% ▲
Management
17% ▲
Science & Research
17% ▼
People
Scott Clarke
Managing Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Tech stack
Technologies named in job postings at Catalym over the last 12 months, by layer, with the share of postings for each.
Technologies in use
3
Postings analysed
4
Stack modernity
64/100
Languages
Python
Cloud & platforms
GCP
Practices & domains
Master Data Management
Sign in to see how your skills match this stack
Sign In
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Jeito CapitalVia a fund
Brandon CapitalVia a fund
Novartis Venture FundVia a fund
BioGeneration VenturesVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
CatalYm Appoints Peter Garcia as Chief Financial Officer
CatalYm Appoints Peter Garcia as Chief Financial Officer Munich, Germany and San Francisco, USA, June 09, 2026 - CatalYm today announced the appointment of Peter Garcia as Chief Financial Officer (CFO). Mr. Garcia brings more than three decades of biotech
Read more
Report
CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors
CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors Munich, Germany and San Francisco, USA, April 28, 2026 - CatalYm today announced the appointment of seasoned biotech executive Christian S. Schade as Chairman of the Board of Direc
Read more
Report
CatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First Patient Dosed
CatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First Patient Dosed Trial will evaluate visugromab's potential to reverse cancer-associated weight loss and muscle wasting by targeting GDF-15 in patients with advanced solid
Read more
Report
CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma
CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma Study targets patients with unresectable or metastatic hepatocellular c
Read more
Report
CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular ...
Read more
Report
Report
Jefferies Global Healthcare Conference in London 2026
November 16 - November 19, 2026 London, UK
Read more
Report
Piper Sandler 38th Annual Healthcare Conference 2026
December 01 - December 03, 2026 New York, NY, USA
Read more
Report
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Metastatic Non-squamous NSCLC
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Metastatic Non-squamous NSCLC Study targets patients with advanced disease who have progressed on prior immuno
Read more
Report
Show more news